Allied-Market-Research-mobile

Coming Up With New Logo

Cart
0
Get 20% Free Customization In This Report

Male Hypogonadism Market by Therapy {Testosterone Replacement Therapy and Gonadotropin & Gonadotropin-Releasing Hormones Therapy [Luteinizing Hormone (LH)], Follicle-Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), and Gonadotropin-Releasing Hormone (GnRH)}, Drug Delivery (Topical Gels, Injectable, Transdermal Patches, and Others), and Type (Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

  • ID: LI 171874
  • Feb 2017
  • 157 pages
  • Price: $4296
$2765

Male Hypogonadism Market Overview:

Global Male Hypogonadism Market is estimated to reach $3,233 million from $2,594 million and is supported by a CAGR of 3.1% during the forecast period. Male hypogonadism is a medical condition in which testes cannot produce enough testosterone, resulting in decreased development of muscle mass, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

The market growth is driven by factors, such as increase in incidence of hypogonadism, rise in awareness about hypogonadism & its treatment option, and growth in infertility rates. In addition, the prevalence of hypogonadism is high in the geriatric population, and patient population with diabetes & obesity. Thus, growth in such population and rise in incidence & prevalence of chronic diseases including diabetes & obesity are expected to boost the market growth. According to various studies, men aged between 60 ‐80 years have low testosterone levels by 20% and 80%, respectively, than normal testosterone levels for young men. Men above 60 years have the highest prevalence of hypogonadism. Countries, such as Japan, China, U.S. and others, with surging geriatric population, witness high demand for therapies used to treat male hypogonadism.

Percentage of Total Population Aged 65 Years & Above by Country

Percentage of Total Population Aged 65 Years & Above

Cautions & warnings issued by the FDA against side effects of TRT products is expected to restrain the market growth during the forecast period. However, novel treatment options are under development, which show positive results in terms of efficacy and they are expected to have lesser or no side effects. Therefore, these advancements are anticipated to create new opportunities during the analysis period.

Segment Review

Testosterone replacement therapy (TRT) held the largest share accounting for more than half of the market, in 2015. However, the segment is expected to witness decreasing growth rate, owing to post application side effects, such as various cardiovascular diseases, blood clots, and stroke. Gonadotropin & gonadotropin-releasing hormones segment is expected to grow at the highest CAGR during the forecast period, owing to rise in adoption of this therapy with surging prevalence hypogonadal men. By drug delivery method, injectable held nearly half of the market share of the total in 2015. By type, pituitary disorders segment was the largest revenue contributor in the aforementioned year.

Geographically, North America held the largest market share (more than three-fourths share) in 2015, and it is anticipated to continue its dominance during the forecast period. Increase in population with hypogonadism owing to rise in in obesity, co-morbidities including diabetes, and poor health in the geriatric population drive the North American market growth. Mexico is expected to grow at the significant CAGR of 6.7% in North America.

Asia-Pacific is estimated to register the highest growth rate in the coming years. This region is densely populated, with India and China being the most populated countries, accounting for major share of the patient population with diabetes & obesity. Japan, China, and others possess the highest aging population; therefore, the prevalence of male hypogonadism is high in these countries. This market growth is supplemented by the increase in men population suffering from infertility. For instance, according to Andrology Australia, androgen deficiency is common and affects 1 in 200 men under 60 years of age. As per the Australian Family Physician Medical Journal, the prevalence of hypogonadism may be up to 12% in men older than 40 years of age. In addition, the increase in healthcare reforms and rise in awareness among people are expected to boost the market growth.

Comprehensive competitive analysis and profiles of major market players, such as AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG., Eli Lilly and Company Ltd., Endo International plc, Merck & Co., Inc., Ferring Holding S.A., Finox Biotech, IBSA Institut Biochimque SA, Laboratoires Genévrier S.A., and Teva Pharmaceutical Industries Ltd., are provided in the report. Other prominent players in the market include Lipocine Inc., Pfizer Inc., Aytu Biosciences, Diurnal Group PLC, Hyundai Pharmaceuticals Co Ltd., Perrigo Company plc, Novus Biologicals, LLC.

Male Hypogonadism Market Report Key Benefits

  • It provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by therapy helps in understanding the various types of therapies used to treat hypogonadism.
  • Comprehensive analysis of all geographical regions is provided, which assist in determining the main opportunities in these geographies.
  • Key players within the market are profiled and their strategies are analyzed thoroughly to determine the competitive outlook of the global market.

Male Hypogonadism Market Key Segmentation:

By Therapy

  • Testosterone Replacement Therapy
  • Gonadotropin and Gonadotropin-Releasing Hormones Therapy
    • Luteinizing Hormone (LH)
    • Follicle-Stimulating Hormone (FSH)
    • Human Chorionic Gonadotropin (hCG)
    • Gonadotropin-Releasing Hormone (GnRH)

By Drug Delivery

  • Topical Gels
  • Injectable
  • Transdermal Patches
  • Others

By Type

  • Klinefelter's Syndrome
  • Kallmann Syndrome
  • Pituitary Disorders
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

List of Key Players Profiled in the Report

  • AbbVie Inc.
  • Allergan plc
  • Astrazeneca plc
  • Bayer AG
  • Eli Lilly and Company Ltd.
  • Endo International plc.
  • Merck & Co., Inc.
  • Ferring
  • Finox Biotech,
  • IBSA Institut Biochimque SA
  • Laboratoires Genevrier
  • Teva Pharmaceutical Industries Ltd.

List of other Players in the Value Chain (These players are not profiled in the report. The same will be included on request.)

  • Lipocine Inc.
  • Pfizer Inc.
  • Aytu Biosciences
  • Diurnal Group PLC
  • Hyundai Pharmaceuticals Co Ltd.
  • Perrigo Company plc
  • Novus Biologicals, LLC
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. TOP PLAYER POSITIONING, 2015
3.5. PATIENTS/PREVALENCE OVERVIEW
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. High risk of hypogonadism in geriatric population
3.6.1.2. Lifestyle issues
3.6.1.3. Rise in infertility rates
3.6.1.4. Increased awareness level lead to market growth

3.6.2. Restraints

3.6.2.1. Cautions & warnings issued by FDA against the side effects of TRT
3.6.2.2. Social taboos

3.6.3. Opportunity

3.6.3.1. Technological advancements

Chapter: 4 MALE HYPOGONADISM MARKET, BY THERAPY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. TESTOSTERONE REPLACEMENT THERAPY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size & forecast

4.3. GONADOTROPIN AND GONADOTROPIN RELEASING HORMONES THERAPY

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size & forecast
4.3.4. LH

4.3.4.1. LH market size and forecast

4.3.5. FSH

4.3.5.1. FSH market size and forecast

4.3.6. hCG

4.3.6.1. hCG market size and forecast

4.3.7. Gonadotropin-releasing hormone

4.3.7.1. GnRH market size and forecast

Chapter: 5 MALE HYPOGONADISM MARKET, BY DRUG DELIVERY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. TOPICAL GELS

5.2.1. Market size and forecast

5.3. INJECTABLES

5.3.1. Market size and forecast

5.4. TRANSDERMAL PATCHES

5.4.1. Market size and forecast

5.5. OTHERS

5.5.1. Market size and forecast

Chapter: 6 MALE HYPOGONADISM MARKET, BY TYPE

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. KLINEFELTER’S SYNDROME

6.2.1. Market size and forecast

6.3. PITUITARY DISORDERS

6.3.1. Market size and forecast

6.4. KALLMANN SYNDROME

6.4.1. Market size and forecast

6.5. OTHER

6.5.1. Market size and forecast

Chapter: 7 MALE HYPOGONADISM MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. China market size and forecast
7.4.5. Japan market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and Opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ABBVIE INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance

8.2. ALLERGAN, PLC

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. ASTRAZENECA PLC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance

8.4. BAYER AG

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Business performance

8.5. ELI LILLY AND COMPANY LIMITED

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments

8.6. ENDO INTERNATIONAL PLC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. FERRING HOLDING S.A.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments

8.8. FINOX BIOTECH (FINOX AG)

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. IBSA INSTITUT BIOCHIMIQUE SA

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance

8.10. LABORATOIRES GENEVRIER S.A.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments

8.11. MERCK & CO., INC.

8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Business performance

8.12. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

8.12.1. Company overview
8.12.2. Company snapshot
8.12.3. Operating business segments
8.12.4. Business performance
8.12.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. MALES BEING TREATED FOR HYPOGONADISM, (VOLUME), 2014-2022 (MILLION)
TABLE 2. MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 3. TESTOSTERONE REPLACEMENT THERAPY MARKET, BY GEOGRAPHY,  2014-2022 ($MILLION)
TABLE 4. GONADOTROPINS AND GONADOTROPINS RELEASING HORMONES THERAPY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 5. MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 6. TOPICAL GEL MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY,  2014-2022 ($MILLION)
TABLE 7. INJECTABLES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY,  2014-2022 ($MILLION)
TABLE 8. TRANSDERMAL PATCHES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9. OTHERS MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10. MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 11. MALE HYPOGONADISM MARKET FOR KLINEFELTER'S SYNDROME,  BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12. MALE HYPOGONADISM MARKET FOR PITUITARY DISORDERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13. MALE HYPOGONADISM MARKET FOR KALLMANN SYNDROME, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 14. MALE HYPOGONADISM MARKET FOR OTHER SYNDROMES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15. MALE HYPOGONADISM MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 16. NORTH AMERICA MALE HYPOGONADISM MARKET, BY COUNTRY,  2014-2022 ($MILLION)
TABLE 17. NORTH AMERICA MALE HYPOGONADISM MARKET, BY THERAPY,  2014-2022 ($MILLION)
TABLE 18. NORTH AMERICA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY,  2014-2022 ($MILLION)
TABLE 19. NORTH AMERICA MALE HYPOGONADISM MARKET, BY TYPE,  2014-2022 ($MILLION)
TABLE 20. EUROPE MALE HYPOGONADISM MARKET, BY COUNTRY,  2014-2022 ($MILLION)
TABLE 21. EUROPE MALE HYPOGONADISM MARKET, BY THERAPY,  2014-2022 ($MILLION)
TABLE 22. EUROPE MALE HYPOGONADISM MARKET, BY DRUG DELIVERY,  2014-2022 ($MILLION)
TABLE 23. EUROPE MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 24. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY COUNTRY,  2014-2022 ($MILLION)
TABLE 25. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY THERAPY,  2014-2022 ($MILLION)
TABLE 26. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY DRUG DELIVERY,  2014-2022 ($MILLION)
TABLE 27. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY TYPE,  2014-2022 ($MILLION)
TABLE 28. LAMEA MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 29. LAMEA MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 30. LAMEA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 31. LAMEA MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 32. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 33. ABBVIE INC.: OPERATING SEGMENTS
TABLE 34. ALLERGAN: COMPANY SNAPSHOT
TABLE 35. ALLERGAN: OPERATING SEGMENTS
TABLE 36. ASTRAZENECA PLC.: COMPANY SNAPSHOT
TABLE 37. ASTRAZENECA PLC.: OPERATING SEGMENTS
TABLE 38. BAYER: COMPANY SNAPSHOT
TABLE 39. BAYER: OPERATING SEGMENTS
TABLE 40. ELI LILLY AND COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 41. ELI LILLY AND COMPANY LIMITED: OPERATING SEGMENTS
TABLE 42. ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT
TABLE 43. ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS
TABLE 44. FERRING: COMPANY SNAPSHOT
TABLE 45. FERRING: OPERATING SEGMENTS
TABLE 46. FINOX AG: COMPANY SNAPSHOT
TABLE 47. FINOX AG: OPERATING SEGMENTS
TABLE 48. IBSA INSTITUT BIOCHIMIQUE SA: COMPANY SNAPSHOT
TABLE 49. IBSA INSTITUT BIOCHIMIQUE SA: OPERATING SEGMENTS
TABLE 50. LABORATOIRES GENÉVRIER: COMPANY SNAPSHOT
TABLE 51. LABORATOIRES GENÉVRIER: OPERATING SEGMENTS
TABLE 52. MERCK: COMPANY SNAPSHOT
TABLE 53. MERCK: OPERATING SEGMENTS
TABLE 54. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 55. TEVA PHARMACEUTICAL: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. MALE HYPOGONADISM MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN MALE HYPOGONADISM MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2013-2015
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP PLAYER POSITIONING, 2015
FIGURE 6. PERCENTAGE OF MEN WITH LOW LEVELS OF TOTAL AND BIOAVAILABLE TESTOSTERONE
FIGURE 7. DECLINING TESTOSTERONE LEVEL WITH INCREASING AGE
FIGURE 8. PERCENTAGE OF TOTAL POPULATION ABOVE 65 YEARS OF AGE
FIGURE 9. LH MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 10. FSH MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 11. HCG MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 12. GNRH MARKET FOR MALE HYPOGONADISM, 2014-2022 ($MILLION)
FIGURE 13. MALE HYPOGONADISM MARKET SEGMENTATION, BY TYPE
FIGURE 14. CAUSES OF MALE HYPOGONADISM
FIGURE 15. U.S. MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 16. CANADA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 17. MEXICO MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 18. GERMANY MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 19. FRANCE MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 20. UK MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 21. REST OF EUROPE MALE HYPOGONADISM MARKET,  2014-2022 ($MILLION)
FIGURE 22. CHINA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 23. JAPAN MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 24. INDIA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 25. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 26. LATIN AMERICA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 27. MIDDLE EAST MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 28. AFRICA MALE HYPOGONADISM MARKET, 2014-2022 ($MILLION)
FIGURE 29. ABBVIE INC.: REVENUE, 2013-2015 ($MILLION)
FIGURE 30. ABBVIE INC.: REVENUE BY SEGMENT, 2015 (%)
FIGURE 31. ABBVIE INC.: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 32. ALLERGAN: REVENUE, 2013-2015 ($MILLION)
FIGURE 33. ALLERGAN: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIGURE 34. ALLERGAN: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 35. ASTRAZENECA PLC.: REVENUE, 2013-2015 ($MILLION)
FIGURE 36. ASTRAZENECA PLC.: REVENUE BY GEOGRAPHY, 2015(%)
FIGURE 37. BAYER: REVENUE, 2013-2015 ($MILLION)
FIGURE 38. BAYER: REVENUE BY SEGMENT, 2015 (%)
FIGURE 39. BAYER: REVENUE BY GEOGRAPHY, 2015(%)
FIGURE 40. ELI LILLY AND COMPANY LIMITED: REVENUE, 2013-2015 ($MILLION)
FIGURE 41. ELI LILLY AND COMPANY LIMITED: REVENUE BY SEGMENT, 2015 (%)
FIGURE 42. ELI LILLY AND COMPANY LIMITED: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 43. ENDO INTERNATIONAL PLC.: REVENUE, 2013-2015 ($MILLION)
FIGURE 44. ENDO INTERNATIONAL PLC.: REVENUE BY SEGMENT, 2015 (%)
FIGURE 45. ENDO INTERNATIONAL PLC.: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 46. MERCK: REVENUE, 2013-2015 ($MILLION)
FIGURE 47. MERCK: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIGURE 48. MERCK: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 49. TEVA PHARMACEUTICAL: REVENUE, 2013-2015 ($MILLION)
FIGURE 50. TEVA PHARMACEUTICAL: REVENUE BY BUSINESS SEGMENT, 2015 (%)
FIGURE 51. TEVA PHARMACEUTICAL: REVENUE BY GEOGRAPHY, 2015 (%)

 

Male hypogonadism is a condition when the testes fail to produce androgen or sperm resulting in deficiency of testosterone, which is responsible for the development of secondary sexual characters in men. The treatment of this condition plays a vital role in maintaining the secondary sexual characters and hormonal balance. Rise in awareness about the available treatment options and increase in incidence of male hypogonadism are major factors that drive the growth of this market.

The testosterone replacement therapy market is witnessing a declining trend owing to growth in awareness about the it side effects such as high risk of cardiovascular diseases associated with its use. The key players in the market are extensively involved in R&D activities in this field to innovate and launch products with lesser or no side effects and better results. For instance, LPCN 1111, a under development product from Lipocine Inc., is a novel ester prodrug of testosterone that uses the Lip'ral technology to enhance systemic absorption and enhance the solubility of testosterone. Similarly, another TRT product, LPCN 1021 from the company is under the review of FDA and is in its third phase of clinical trial. These products are expected to be less harmful as compared to the current TRT topical gels in the market, and pave way for new opportunities in this market.

Geographically, the Asia-Pacific market offers lucrative growth opportunities due to increase in demand for better healthcare services in emerging economies (India and China), rise in incidence & prevalence of hypogonadism & infertility rates in the region coupled with growth in the geriatric population patient population with diabetes & obesity. China, Malaysia, and Taiwan are the few top countries with highest rate of male hypogonadism.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, For any queries, please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASK
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts